MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Abroad (travel likely)RecruitingPHASE2

Conditions

AML · MDS · Acute Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndromes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Acute Myeloid Leukemia (AML) · Myelodysplastic Syndromes (MDS)

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Guangzhou, China

Haplo-Cord HSCT for AML/MDS

MDS (Myelodysplastic Syndrome) · AML (Acute Myeloid Leukemia)

Abroad (travel likely)Recruiting

Fuzhou, China · Guangzhou, China

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory · MDS (Myelodysplastic Syndrome)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Charlotte, United States · Winston-Salem, United States